(Q30371832)

21 June 2017

1 reference

title

Immunotherapy for HCV infection: next steps. (English)

1 reference

21 June 2017

1 reference

Krystle Lang

1

1 reference

21 June 2017

David B Weiner

series ordinal

2

1 reference

21 June 2017

publication date

1 September 2008

1 reference

Expert Review of Vaccines

21 June 2017

published in

1 reference

21 June 2017

volume

7

1 reference

21 June 2017

issue

7

1 reference

21 June 2017

page(s)

915-923

1 reference

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

The way forward in HCV treatment--finding the right path

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Adaptive immune responses in acute and chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Prospects for a vaccine against the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Cross-genotype immunity to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Diagnostic tests for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Analysis of a successful immune response against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Hepatitis C virus--biology, host evasion strategies, and promising new therapies on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Hepatitis C virus variability: sequence analysis of an isolate after 10 years of chronic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Determinants of viral clearance and persistence during acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Analysis of successful immune responses in persons infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Vaccination of chimpanzees against infection by the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Sustained Dysfunction of Antiviral CD8+ T Lymphocytes after Infection with Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Electropermeabilization of skeletal muscle enhances gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.915

21 January 2018

Identifiers

DOI

10.1586/14760584.7.7.915

1 reference

21 June 2017

1 reference